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Abstract: Cardiovascular diseases are the main cause of mortality and morbidity in the world.
Hypertension, ischemia/reperfusion, diabetes and anti-cancer drugs contribute to heart failure
through oxidative and nitrosative stresses which cause cardiomyocytes nuclear and mitochondrial
DNA damage, denaturation of intracellular proteins, lipid peroxidation and inflammation. Oxidative
or nitrosative stress-mediated injury lead to cardiomyocytes apoptosis or necrosis. The reactive
oxygen (ROS) and nitrogen species (RNS) concentration is dependent on their production and on the
expression and activity of anti-oxidant enzymes. Polyphenols are a large group of natural compounds
ubiquitously expressed in plants, and epidemiological studies have shown associations between a
diet rich in polyphenols and the prevention of various ROS-mediated human diseases. Polyphenols
reduce cardiomyocytes damage, necrosis, apoptosis, infarct size and improve cardiac function by
decreasing oxidative stress-induced production of ROS or RNS. These effects are achieved by the
ability of polyphenols to modulate the expression and activity of anti-oxidant enzymes and several
signaling pathways involved in cells survival. This report reviews current knowledge on the potential
anti-oxidative effects of polyphenols to control the cardiotoxicity induced by ROS and RNS stress.
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1. Introduction
Cardiovascular diseases are the main cause of mortality and morbidity in the world [1].
Hypertension, ischemia, diabetes, anti-cancer drugs contribute to heart failure through oxidative
and nitrosative stresses which induce nuclear and mitochondrial DNA damage, denaturation of
intracellular proteins, lipid peroxidation and inflammation in cardiomyocytes [2,3]. Oxidative
or nitrosative stress-mediated injury lead to cardiomyocytes apoptosis or necrosis [2,3]. Reactive
oxygen (ROS) and nitrogen species (RNS) concentration is dependent on their production and on the
expression and activity of anti-oxidant enzymes [2]. ROS production is influenced by many factors,
such as dysfunction of oxidative enzymes (xanthine oxidase (XO), aldehyde oxidase, nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase and uncoupled nitric oxide synthase (NOS)),
dysregulation of mitochondria, microsomes and/or nuclei transport, neutrophil activation, arachidonic
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acid metabolism and auto-oxidation of catecholamines, flavins, quinones and proteins [4,5]. The main
ROS and RNS are superoxide, hydrogen peroxide, hydroxyl radical, nitric oxide (NO) and peroxynitrite.
The production of hydrogen peroxide regulates the expression of genes, in particular those activated
by nuclear factor-kappa B (NF-κB), and the overload of Ca2+ levels in cardiomyocytes subjected to
heart failure. The nitric oxide initiates lipid peroxidation and produces, by interacting with superoxide
anion, peroxynitrite which is implicated in atherosclerosis [4]. Peroxynitrites trigger lipid peroxidation,
protein oxidation, nitration and activation of matrix metalloproteinases (MMPs) [6]. However, NO can
also maintain inactive the oxidant enzymes (XO and NADPH oxidase) and balance the superoxide/NO
ratio [6]. In addition, iron and copper are the principal metal ions that induce the production of ROS
by Fenton or Haber-Weiss reactions. Iron and copper enhance the lipid peroxidation and production
of free radicals, including alkyl, alkoxy, peroxy and hydroxyl radicals. Conversely, selenium is an
important anti-oxidant ion which regulates the glutathione peroxidase (GSH-Px) [4].
The mitochondria are identified as a major source of ROS production in several organs with
high metabolic activity, for example in the heart [7]. Enzymes that produce ROS, both in membrane
(NADPH oxidase) and in matrix (tricarboxylic acid cycle, TCA) are present in the mitochondria. Under
normal conditions, ROS levels are low for the intra-mitochondrial presence of anti-oxidant systems.
The increase of ROS production simultaneously to the inhibition of anti-oxidant systems and/or of
ETC (electron transport chain) complex increase ROS levels [7]. Furthermore, sirtuins (SIRTs), localized
in the mitochondria, play an essential role in cardiovascular disease and influence energy metabolism,
DNA repair and oxidative stress. Sirtuins induce the deacetylation of forkhead box O (FoxO), NF-κB,
protein kinase B (Akt), p53, superoxide dismutase (SOD), and members of ETC complex I and influence
fatty acid oxidation, cardiac hypertrophy, ischemia/reperfusion (I/R) injury, apoptosis, oxidative stress
and autophagy in cardiomyocytes [8]. Angiotensin (Ang) II, platelet-derived growth factor (PDGF),
and tumor necrosis factor (TNF)-α induce the production of ROS in the cardiac muscle through the
NADPH oxidase and then cardiomyocytes apoptosis, cardiac hypertrophy, reduction of myofilament
sensitivity and cardiac contractility [9].
Several enzymatic and non-enzymatic mechanisms balance the production of ROS and transform
ROS into non-toxic molecules in myocardium, as in other organs [9]. An anti-oxidant enzyme is SOD,
which is present in three forms, copper-zinc SOD (CuZnSOD or SOD1), manganese SOD (MnSOD or
SOD2) and extracellular SOD (EC-SOD or SOD3) [8]. Other enzymes, including the catalase (CAT)
and GSH-Px reduce the production of ROS. SOD converts superoxide in hydrogen peroxide, which is
transformed into water and oxygen by CAT and GSH-Px. Thioredoxin and thioredoxin reductase form
an additional system that blocks ROS production through protein-disulfide oxidoreductase activity.
Intracellular non-enzymatic anti-oxidants are vitamins E and C, β-carotene, ubiquinone, lipoic acid,
urate and glutathione [6,10]. Anti-oxidant enzymes are activated during oxidative stress and after
activation of cytokines. However, these enzymes are down-regulated during the end stage of heart
failure [10].
Recently, many studies identified the potential anti-oxidant effects of polyphenols in cardiac
diseases. Polyphenols can reduce the cardiac damage due to ROS and RNS production [11] (Figure 1).
In this review, we report the last ten years researches on the potential effects of polyphenols in
modulating the cardiotoxicity induced by ROS or RNS.
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Figure 1. Generation of reactive oxygen species (ROS) and their cellular effects. 
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in foods are flavonols, flavones, flavan-3-ols, anthocyanins, flavanones and isoflavones. The 
subclasses of dihydroflavonols, flavan-3,4-diols, chalcones, dihydrochalcones, and aurones are minor 
components of our diet. The most important classes of non-flavonoids are phenolic acids, stilbenes 
and lignans [14–16] (Figure 2). 
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Epidemiological studies have shown associations between a diet rich in polyphenols and the 
prevention of human diseases [12,17–21]. Polyphenols are natural anti-oxidants present in the human 
diet. This activity is related to their metal ions chelating and free radical scavenger properties. 
Structural features of polyphenols allow them to act as direct free radical scavengers, such as the 
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double bond in conjugation with a 4-oxofunction of a carbonyl group in the C-ring [22]. However, 
polyphenols can also behave as pro-oxidants at high doses or in the presence of metal ions, leading 
to DNA degradation. However, there is no evidence of sistemic pro-oxidant effect of polyphenols in 
humans [23]. 
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2. Polyphenols
2.1. Classification
Polyphenols are a large group of natural compounds found in foods and beverages of plant origin
(fruits, vegetables, cereals, herbs, spices, legumes, nuts, olives, chocolate, tea, coffee, and wine) [12,13].
Polyphenols are classified in flavonoids and non-flavonoids, according to the number of phenol
rings and structural elements bound to these rings. The most important classes of flavonoids found in
foods are flavonols, flavones, flavan-3-ols, anthocyanins, flavanones and isoflavones. The subclasses of
dihydroflavonols, flavan-3,4-diols, chalcones, dihydrochalcones, and aurones are minor components of
our diet. The most important classes of non-flavonoids are phenolic acids, stilbenes and lignans [14–16]
(Figure 2).
2.2. Polyphenols and Oxidative Stress and Epigenetic Regulation
Epidemiological studies have shown associations between a diet rich in polyphenols and the
prevention of human diseases [12,17–21]. Polyphenols are natural anti-oxidants present in the human
diet. This activity is related to t eir et l i s chelating and free radical scavenger properties.
Struct ral features of polyphenols al o t t s irect fr e radical scavenger , such as the
catechol group on the B-ri t e presence of hydroxyl groups at the 3 and 5 position and the
2,3-double bond in conjugation with a 4-oxofunction of a carbonyl group in the C-ring [22]. However,
polyphenols can also behave as pro-oxida ts at i ses or in the presence of metal ions, leading
to DNA degradation. However, there is no evidence of siste ic pro-oxidant effect of polyphenols in
humans [23].
It is of note that the direct anti-oxidant activity of polyphenols appears to be ineffective
in vivo, because of the low bioavailability and kinetic constraints, and it has been proposed that
the beneficial effects observed are due to an indirect anti-oxidant effect rather than to their direct
free radical scavenger properties. Indeed, it has been demonstrated that polyphenols possess an
indirect anti-oxidant capacity by modulating genes expression and by inducing the endogenous
anti-oxidant enzymatic defense system [24–26]. The indirect modality of oxidative stress protection
and the health benefits exerted by polyphenols are due to the hormetic mechanism of action.
Polyphenols activate adaptive cellular response pathways (hormetic pathways) that induce the
expression of genes encoding for anti-oxidant enzymes, phase-2 enzymes, protein chaperones and
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survival-promoting proteins. Example of these pathways are the Keap1/Nrf2/ARE, the Sirtuin-FoxO
and the NF-κB pathways [27,28]. In particular, it has been demonstrated that polyphenols activate
the Keap1/Nrf2/ARE pathway through an oxidative mechanism. In fact, polyphenols must be
metabolized into electrophilic compounds for inactivating the inhibitor Keap 1 and thus activating
Nrf2, a transcription factor regulating the expression of most Phase II and some Phase III genes [26].
By transcription-mediated signalling, polyphenols exert long-lasting effects as compared to other direct
anti-oxidant agents [27,29]. However, the hypothesis of activation of Phase II enzymes by polyphenols
has not been proven in human yet [28,30].Nutrients 2017, 9, 523  4 of 43 
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Several studies reported that epigenetic mechanisms are involved in the development and
progression of different diseases, including cardiovascular diseases [31]. Polyphenols can reduce
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the risk of cardiovascular disease by interacting with signaling cascades and epigenetic factors [32].
Several evidence reported that epigenetic mechanisms are involved in hormesis-like responses [33].
Epigenetic modifications depend on the cell type and the stage of the cardiovascular disease. For
example, the global DNA is hypermethylated in the early stage of atherosclerosis and hypomethylated
in the atherosclerotic lesions, while the peripheral blood leucocytes show global hypermethylation of
DNA. In addition, the methylation or acetylation of DNA regulatory regions up- or down-regulate
the expression of genes involved in cardiovascular diseases [34]. Polyphenols can reduce DNA
methylation, as well as histone modifications and can modify the expression of transcription factors
by epigenetic regulation [32,34–36]. Polyphenols silence chromatin by the inhibition of DNA
methyltransferases and the activation of class III histone deacetylases (commonly called sirtuins) in
vascular endothelium. These effects occur in atherosclerosis and other cardiovascular diseases [36,37].
MicroRNAs (miRNAs) are non-coding RNAs which modify the transcription with no interference
with DNA sequences [34]. miRNAs regulate gene transcription through the degradation or repression
of mRNA. Various miRNAs are also associated with cardiovascular diseases as biomarkers [34].
For example, increased levels of miRNA-1, miRNA-133b and miRNA-499 are observed in acute
myocardial infarction [38,39]. Elevated levels of miRNA-217 are associated with inhibited expression of
SIRT1 in atherosclerosis [40]. However, the levels of several miRNAs can also decrease in cardiovascular
diseases. In fact, miRNA-126 and miRNA-145 levels decrease in patients with coronary artery disease [41].
Polyphenols modulate the expression of several miRNAs [42]. For example, resveratrol regulates
the cardiac function through the expression of miRNA-20b, miRNA-149, miRNA-133, miRNA-21,
and miRNA-27 [32]. In addition, it has been reported that resveratrol exerts cardioprotective effects
through the up-regulation of miRNA-21 and SIRT1 expression in ischemic rats. miRNA-21 regulates
cardiac remodeling, cardiac cell growth and apoptosis [43].
In vitro studies underlying molecular mechanisms through which polyphenols affect oxidative
stress-induced cardiotoxicity are reported below.
3. In Vitro Effects of Polyphenols Against Oxidative Stress-Induced Cardiotoxicity
3.1. Flavonoids
3.1.1. Flavonols
Flavonols are the most common flavonoids present in plant-derived foods, wine and tea.
Quercetin, kaempferol and myricetin are the main flavonols [17].
Several studies investigated the effect of flavonols against H2O2-induced cardiotoxicity. Quercetin
or 3′-O-methyl quercetin treatment (30 µM) or rhamnetin, from berries of Rhamnus petiolaris, (1, 3,
5 µM) treatment of rat/H9c2 cardiomyocytes exposed to H2O2 decreased ROS production and
number of death cells by up-regulating the NQO-1, HO-1, TR (thioredoxin reductase 1), and total
glutathione S-transferase (GST) activities or by inhibiting MAPKs activation [44–46]. Conversely,
3′,4′-dihydroxyflavonol (DiOHF, 10 µM) protected rat cardiomyocytes against H2O2-induced oxidative
stress by increasing the phosphorylation of MAPKs and Akt and regulated the activation of the
reperfusion injury survival kinase (RISK) pathways [47].
Doxorubicin (DOX)/Adriamycin is an anthracycline antibiotic used in chemotherapy and it is
associated with cardiotoxicity. The treatment of H9c2 cardiomyocytes with quercetin (50, 100 µM),
isorhamnetin (6.25–25 µg/mL), kaempferol (20 µM) or dihydromyricetin (50 µM, a flavonoid
extracted from Ampelopsis grossedentata), decreased the DOX-induced apoptosis, ROS production,
lipid peroxidation and NADPH oxidase activity. Isorhamnetin also increased the production of
anti-oxidant enzymes and modulated MAPK activity [48–51].
Quercetin pretreatment (20 µM) of H9c2 cardiomyocytes significantly attenuated trauma-induced
apoptosis, TNF-α levels, ROS production and Ca2+ levels [52].
PKCε, a member of the PKC family of serine and threonine kinases, regulates several processes,
including mitogenesis, cell survival, metastasis and transcriptional regulation. The treatment of rat
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cardiomyocytes with quercetin (40 µM) or kaempferol (20 µM) before anoxia/reoxygenation (A/R)
mediated-injury increased PKCε, cells viability and the expression of SIRT1, decreased apoptosis
and ROS generation and restored the mitochondrial membrane potential [53,54]. The incubation of
sheep myocardial tissues with DiOHF (10−4–10−6 M) blocked ROS production after myocardial I/R
injury [55].
Taxifolin (5–50 µM), a derivative of dihydroquercetin, reduced hypertrophy, ROS generation and
protein synthesis induced by Ang II in neonatal rat cardiomyocytes [56].
The effects of quercetin and hydroxytyrosol, present in the leaves of olive (Olea europaea L.), have
been evaluated in H9c2 cardiomyocytes exposed to xanthine/XO-induced oxidative stress. Both
quercetin and hydroxytyrosol (0.1, 10 µg/mL) reduced the number of death cells, ROS generation
and the phosphorylation of the MAPK-activated protein kinase 2 (MAPKAPK-2) after exposure to
xanthine/XO [57].
3.1.2. Flavones
Flavones are found in plants as 7-O-glycosides. The most abundant flavones in foods are apigenin
(parsley, celery, onion, garlic, pepper, chamomile tea) and luteolin (Thai chili, onion leaves, celery).
Others flavones, less abundant in edible plants, are tangeretin, nobiletin, baicalein, wogonin and
chrysin [17].
The effect of apigenin and vitexin (a flavone glycoside of apigenin isolated from the leaf
of Crataegus pinnatifida Bunge) on A/R injury was recently assessed in H9c2 and neonatal rat
cardiomyocytes. Apigenin (40 µM) or vitexin (10, 30 and 100 µM) were able to increase cells viability
and to decrease ROS generation, cells apoptosis and necrosis [58,59].
Vitexin has also been shown to possess significant protective effects against myocardial I/R
injury in isolated rat hearts. Hearts were perfused with vitexin (50, 100, 200 µM) for 20 min before
ischemia. Treatment with vitexin inhibited I/R-induced reduction of coronary flow and decreased
I/R-induced histopathological alterations of myocardium, inflammatory cytokines and it inhibited
apoptosis [60]. Baicalein from the root of Scutellaria baicalensis was analyzed for its anti-oxidative effects
in chick cardiomyocyte models during hypoxia, simulated I/R, or mitochondrial complex III inhibition
with antimycin A. Baicalein (10–100 µM) was able to scavenge ROS and to decrease the number of
death cells in all different models [61]. Recently, it has been proven that baicalein protected H9c2
cardiomyocytes and also human embryonic stem cells-derived cardiomyocites (hESC-CMs) against
oxidative stress-induced cell injury. Baicalein (10, 30 µM) decreased ROS generation and the number
of death cells and activated Nrf2 pathway [62].
Conversely, Chang et al. reported that preconditioning with baicalein (10 µM) for a brief time
before I/R injury protected chick embryonic ventricular myocytes from apoptosis through mitochondrial
pro-oxidant mechanisms. Thus, the authors hypothesized that the oxidant-mediated protective effects
of baicalein was probably due to the modulation of mitochondrial pro-oxidant signaling as well [63].
Baicalein (1 µM) also reduced H/R-induced myocardium necrosis and apoptosis through µ- and
δ-opioid but not κ-opioid receptors pathways in chick embryonic cardiomyocites [64].
3.1.3. Flavan-3-Ols
The flavan-3-ol subclass includes several compounds with different chemical structures that
can be divided in monomers, (+)-catechin, (−)-epicatechin, (+)-gallocatechin, (−)-epigallocatechin,
(−)-epicatechin-3-O-gallate, (−)-epigallocatechin-3-O-gallate (EGCG), and polymers (proanthocyanidins).
They are found in fruits, berries, cereals, nuts, chocolate, red wine, and tea [17].
Several studies investigated the effects of flavan-3-ols in cardiomyocytes exposed to exogenous
and endogenous oxidant stress. Pretreatment of rat cardiomyocytes exposed to H2O2 with EGCG
(20, 50 µM or 50–100 mg/L) and theaflavin-3,3′ digallate (TF3, 20 µM) decreased ROS production,
cellular damage and apoptosis through the inhibition of telomere dependent apoptotic pathway [65–68].
EGCG (50 µM) was also able to protect H9c2 cardiomyocytes from H2O2-induced changes in the
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expression of β-catenin, N-cadherin and the gap junction protein Cx43 and to activate caveolin-1 by
modulating Akt/GSK-3β signaling [66].
Other studies investigated the cardioprotective role of flavan-3-ols in cardiomyocytes exposed to
DOX. EGCG (25, 38, 50, or 100 µM) and grape seed proanthocyanidin extract (GSPE, 50 µg/mL) protected
rat cardiomyocytes against DOX-induced oxidative stress by reducing apoptosis, ROS generation
and the distruption of mitochondrial membrane potential, and by increasing anti-oxidant enzymes
and by reversing DOX-induced intracellular Ca2+ depletion in the sarcoplasmic reticulum [69–71].
GSPE prevented cardiotoxicity induced by DOX, without interfering with DOX anti-neoplastic activity
in primary cultures of cardiomyocytes [71]. Two studies showed the role of flavan-3-ols against
toxicity induced by I/R injury. EGCG (10, 100 µM), and GSPE (50 µg/mL) protected rat and chick
cardiomyocytes from I/R-induced apoptosis and cellular damage [72,73]. Similarly, Hirai et al.
evaluated the cardioprotective effects of EGCG and the catechin epimer (GCG) in isolated guinea-pig
Langendorff hearts subjected to I/R. EGCG (3× 10−5 M) or GCG (3× 10−6 M) was introduced into the
perfusate 4 min before ischemia and during reperfusion. EGCG and GCG improved the recovery of left
ventricular end diastolic pressure (LVDP), increased the tissue levels of ATP and phosphocreatine and
inhibited apoptosis [74]. Wei and Meng analyzed the effect of EGCG against bisulfite/sulfite, an agent
that induces sulfur- and oxygen-based free radicals and affects voltage-gated sodium (Na+) channels
(VGSC), or lead in rat ventricular myocytes. EGCG (30 µg/mL) increased anti-oxidant enzymes and
decreased ROS levels and lipid peroxidation in ventricular myocytes of rats exposed to sulfite or
lead [75,76]. EGCG also protected Na+ channels against the oxidative damage induced by sulfite [75].
An in vitro study observed the effects of flavonoids isolated from Lindera erythrocarpa in H9c2
cardiomyocytes exposed to BSO (buthionine-(S,R)-sulfoximine), an inducer of oxidative stress and
cell death. It was found that (−)-epicatechin (3 µM), avicularin (3 µM) and quercitrin (3 µM) had the
ability to inhibit BSO-induced cardiomyocytes death [77].
3.1.4. Anthocyanins
Anthocyanins are a subclass of more than 550 compounds. The most abundant anthocyanins are
cyanidin, pelargonidin, delphinidin, peonidin, petunidin, and malvidin. They occur in two forms:
the aglycone form (anthocyanidin) and the heteroside form (anthocyanin). They are found mainly in
berries, cherries, red grapes, and currants [17].
Two studies evaluated the effects of malvidin, an anthocyanidine present in red wine,
and cyanidin-3-O-glucoside (Cy3G) in isolated rat hearts after I/R. Pretreatment with malvidin
(10−7 M) or Cy3G (20 µM) increased left ventricular (LV) pressure, reduced cells apoptosis and
necrosis [78,79].
Louis et al. investigated the in vitro effect of blueberry phenol fractions (BF) to prevent the
pathologic damage induced by norepinephrine (NE) in adult rat cardiomyocytes. NE induced cells
hypertrophy and death by activating calpains. Pretreatment with BF (6.55 µg/mL) reduced activation
of calpains and apoptosis and increased activity of anti-oxidant enzymes [80].
3.1.5. Flavanones
Flavanones are found mainly in citrus fruits and occur as aglycones, mono- and di-glycosides.
Naringenin and hesperetin are the most important aglycones; neohesperidin (hesperetin-7-O-
neohesperidoside) and naringin (naringenin-7-O-neohesperidoside) are neohesperidosides, and
hesperidin (hesperetin-7- O-rutinoside) and narirutin (naringenin-7-O-rutinoside) are rutinosides [17].
Naringenin (NGN) was proven to possess a cytoprotective effect against oxidative stress by
up-regulating the transcription of Nrf2 and its target genes (GCL and NQO-1). Indeed NGN (50 µM)
protected H9c2 cardiomyocytes from H2O2-mediated cells death, reduced lipid peroxidation and
increased the activity of anti-oxidant enzymes [81].
Several studies demonstrated that naringin was able to protect H9c2 cardiomyocytes against
high glucose (HG)-induced injury. Pretreatment with naringin (5 or 80 µM) increased cells
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viability and reduced the number of apoptotic cells, and dissipation of mitochondrial membrane
potential (MMP). Naringin protected H9c2 cardiomyocytes by inhibiting ROS production and
activation of MAPKs [82–84]. Naringin also confered protection against A/R-induced injury in H9c2
cardiomyocytes. Pretreatment with naringin (10, 20, 40 µg/mL) inhibited apoptosis and oxidative
stress. Naringin protected H9c2 cardiomyocytes through the activation of ERK1/2, PKCδ, Akt and
then the activation of Nrf2 signaling pathway [85].
Several studies analyzed the effect of naringenin-7-O-glucoside (NARG) extracted from Chinese
traditional medicine herb Dracocephalum Rupestre against DOX-induced oxidative stress and apoptosis.
NARG (5–40 µM) reduced DOX-induced apoptosis, necrosis, ROS generation and it up-regulated the
expression of endogenous anti-oxidant enzymes in H9c2 cardiomyocytes [86–88].
Yang et al. demonstrated that hesperetin (25 µM) exerted an anti-apoptotic effect in LPS-stimulated
H9c2 cardiomyocytes, through the mitochondria-dependent intrinsic apoptosis pathway [89].
3.1.6. Isoflavones
Isoflavones are classified as phyto-estrogens for their chemical structure. They are found in
soybeans, soy products, and leguminous plants. Isoflavones are present in plant food mainly as
aglycones (genistein, daidzein) and glycosides (genistin, daidzin, puerarin) [17].
Puerarin, a bioactive daidzein glucoside derived from Radix puerariniae, was studied for its effects
on Ang II-induced cardiac hypertrophy. In vitro pretreatment of neonatal murine cardiomyocytes with
puerarin (50, 100 µM) decreased NADPH oxidase activity, inhibited ROS production and the activation
of oxidative stress-related signaling pathways [90].
Calycosin, an O-methylated isoflavone derived from Astragali radix, has been evaluated for
its effects on oxidative stress-induced apoptosis in H9c2 cardiomyocytes. It has been found that
pretreatment with calycosin (5, 10, 20 µM) enhanced the expression and activation of ERα/β and Akt
phosphorylation and inhibited H2O2-induced cell injury and apoptosis [91].
3.1.7. Chalcones and Dihydrochalcones
Chalcones occur in tomatoes, licorice, shallots and bean sprouts, while dihydrochalcones are
present in apples [17].
Several studies reported the important role of chalcones against I/R injury. Isolated rat hearts,
pretreated with licochalcone D (1 µg/mL) or licochalcone B (0.5, 1 µg/mL) and then subjected to
I/R, showed decreased apoptosis, decreased expression of pro-inflammatory cytokines, reduced cells
necrosis and increased expression of anti-oxidant enzymes. The authors supposed that licochalcone
D exerted these effects through the activation of Akt and the block of NF-κB/p65 and p38 MAPK
pathways [92,93]. Isoliquiritigenin treatment (100 µM) of cardiomyocytes isolated from hearts with I/R,
activated the AMP-activated protein kinase (AMPK) and MAPKs signaling pathways while reduced
the mitochondrial potential and cardiac ROS levels [94]. It has been reported that safflor yellow A
(SYA), a chalcone extracted from Carthamus tinctorius, and hydroxysafflor yellow A (HSYA) protected
H9c2 and primary cultured neonatal rat cardiomyocytes exposed to A/R. The treatment with SYA
(40, 60, 80 nM) or HSYA (20 µM) before A/R injury increased the levels of anti-oxidant enzymes and
decreased cells necrosis and apoptosis through the up-regulation of HO-1 expression [95,96].
Another study investigated the in vitro effect of L6H9, a novel chalcone derivative, in the
pathogenesis of diabetic cardiomyopathy (DCM). The treatment with L6H9 (10 µM) before incubation
with glucose decreased the levels of pro-inflammatory cytokines, pro-apoptotic proteins and ROS
in H9c2 cardiomyocytes. In addition, L6H9 increased the expression of Nrf2 and Nrf2-downstream
anti-oxidant genes and inhibited fibrosis and hypertrophy [97].
Dludla et al. performed a study on the effects of a popular South African herbal tea, rooibos,
produced from the leaves and stems of Aspalathus linearis, on diabetic cardiomyopathy (DCM).
The authors evaluated the effects of an aqueous extract of fermented rooibos (FRE), containing
the chalcone aspalathin and the flavonoids isoorientin, orientin, quercetin-3-O-robinobioside, in
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cardiomyocytes isolated from STZ-induced diabetic rats. Pretreatment of cardiomyocytes with FRE
(1 and 10 µg/mL) protected cardiomyocytes against experimentally induced oxidative stress and
ischemia [98]. Another study demonstrated that aspalathin, found in Aspalathus linearis (rooibos),
protected H9c2 cardiomyocytes from chronic hyperglycemia-mediated apoptosis, by inhibiting the
loss of mitochondrial membrane potential and ROS production and by increasing anti-oxidant
enzymes [99].
3.2. Phenolic Acids
Phenolic acids are derivatives of benzoic acid and cinnamic acid and include the hydroxybenzoic
acids (protocatechuic acid, and gallic acid) and the hydroxycinnamic acids (caffeic acid, ferulic acid,
p-coumaric acid, and sinapic acid). The formers are found in few edible plants, while the laters are
found in fruits, coffee, and cereal grains [17]. Phenolic acids were able to protect cardiomyocytes against
H2O2-induced injury [100–104]. Gui-ling-gao (GLG, also known as turtle jelly) is a traditional food in
Southern China and Hong Kong. Li et al. revealed nine compounds in GLG using mass spectrometry:
caffeoylquinic acid, 5-O-caffeoylshikimic acid, astilbin, 3,4-dicaffeoylquinic acid, 4,5-dicaffeoylquinic
acid, neoisoastilbin, isoastilbin, engeletin and 3,5-dicafeoyylquinic acid. GLG (1.372 mM) had the
ability to scavenge free radicals and to abolish hemolysis, an index of oxidative damage. GLG increased
cell survival and reduced apoptosis in H9c2 cardiomyocytes exposed to H2O2 [100]. Castanea sativa
Mill. (CSM)-bark extract contains tannins and phenolic compounds, including ellagic acid, gallic
acid, and 4 ellagitannins (vescalin, castalin, vescalagin and castalagin). Pretreatment with CSM-bark
extract (50, 100 µg/mL) of neonatal rat cardiac myocytes for 24 h prior to H2O2 exposure protected
cells from oxidative stress-induced injury [101]. Phellinus linteus is a medicinal mushroom rich of a
phenolic compound, the hispidin. H9c2 cardiomyocytes treated with hispidin (30 µM) prior to H2O2
exposure, showed increased cell viability, reduced cells necrosis and ROS generation. In addition,
hispidin decreased H2O2-induced apoptosis through the activation of Akt/GSK3β and MAPKs [102].
Neonatal rat cardiac myocytes (RCMs) pretreated with methyl gallate (50 µM) for 30 min prior to
exposure to cobalt or H2O2, showed reduced apoptosis and ROS levels [103]. Ku et al. compared the
in vitro effect of caffeic acid (CA) and pyrrolidinyl caffeamide (PLCA), a derivative of CA. HL-1, a
mouse atrial cardiomyocyte cell line, was pretreated with CA and PLCA (3 µM) for 1 h before H2O2
administration. PLCA reduced the production of ROS and increased cells viability more than CA. In
addition, PLCA treatment preserved the expression of anti-oxidant enzymes in cardiomyocytes [104].
Song et al. demonstrated the cytoprotective effect of ferulic acid (1, 5, or 10 µg/mL) in hepatocytes
and cardiomyocytes against HG-induced injury and oxidative stress [105].
Atale et al. analyzed the effect of gallic acid-enriched methanolic Syzygium cumini pulp extract
(MPE) on cardiotoxicity induced by malathion, an organophosphate pesticide. MPE treatment (20 µg/mL)
restored the integrity of extra cellular matrix components and reduced the malathion-induced oxidative
stress in H9c2 cardiomyocytes [106].
The beneficial effects of caffeic, chlorogenic and rosmarinic acids against DOX-induced toxicity
were investigated in neonatal rat cardiomyocytes. Hydroxycinnamic acids (100, 200 µM) attenuated
DOX-induced cell damage and the iron-dependent DOX-induced lipid peroxidation of microsomal
and mitochondrial membranes [107].
Danshensu (3-(3,4-dihydroxyphenyl)-2-hydroxypropanoic acid) is the major water-soluble active
component of Danshen, the dried root of the traditional Chinese herb Salvia miltiorrhiza, and it has
been analyzed for its cardioprotective effects. Treatment with danshensu (10 µM) during reperfusion
protected H9c2 cardiomyocytes from I/R-induced apoptosis [108]. Similarly, isolated rat hearts,
perfused with danshensu (1, 10 µM) for 20 min and then subjected to I/R, showed reduced cells
necrosis and ROS production and increased activity of anti-oxidant enzymes. These effects were
achieved by the activation of Akt/ERK1/2/Nrf2 signaling pathways [109].
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3.3. Lignans
Lignans (ecoisolariciresinol, matairesinol, medioresinol, pinoresinol, and lariciresinol) are found
in high concentration in linseed and in minor concentration in algae, leguminous plants, cereals,
vegetables, and fruits [17].
Two studies investigated the transduction pathways involved in the cytoprotective effect of (−)
schisandrin B (Sch B), the most abundant dibenzocyclooctadiene lignan in S. chinensis (Turcz.) Baill, in
H9c2 cardiomyocytes. The treatment of H9c2 cardiomyocytes with (−)Sch B (15 or 20 µM) activated
the MAPKs, increased the nuclear expression of Nrf2 and reduced the H/R-induced apoptosis and
inflammation [110,111]. Chang et al. showed that the treatment with deoxyschizandrin (DSD, 1 µM)
and schisantherin A (STA, 1 µM) reduced apoptosis in cardiac cells subjected to I/R [112].
Cho et al. investigated the effect of syringaresinol in modulating HIF-1 (hypoxia inducible factor-1)
during H/R injury. Syringaresinol (25 µM) protected H9c2 cardiomyocytes against H/R induced-cells
damage, and reduced apoptosis. In addition, syringaresinol suppressed the expression of HIF-1 but
stimulated the nuclear expression and activation of FoxO3, which decreased the expression of ROS
and increased the expression of anti-oxidant enzymes [113].
Su et al. evaluated the in vitro effect of sesamin in DOX-induced citotoxicity in H9c2 cardiomyocytes.
Treatment with sesamin (40 µM) increased cells viability, reduced the release of free radicals and the
mitochondrial damage induced by DOX [114]. Zheng et al. demonstrated that sesamin treatment
reduced the Ang II-induced apoptotic rate and ROS production in H9c2 cardiomyocytes [115].
3.4. Stilbenes (Resveratrol)
The main dietary source of stilbenes is resveratrol (3,5,4′-trihidroxystilbene) from red wine,
grapes, berries, plums, peanuts, and pine nuts [17]. Many studies investigated the protective effects
of resveratrol against H2O2-induced damage in cardiomyocytes. Resveratrol treatment (10–50 µM)
protected H9c2 cardiomyocytes from H2O2-induced cell injury, apoptosis and autophagy and reduced
ROS generation through activation of SIRT1 and mitochondrial biogenesis signaling pathways [116–118].
Movahed et al. also demonstrated that pretreatment with resveratrol (30 µM) prevented necrosis
and the reduction of anti-oxidant enzymes activity in H2O2-exposed adult rat cardiomyocytes [119].
In addition, resveratrol treatment (50 µM) was effective in protecting rabbit ventricular myocytes
against the oxidative stress-induced arrhythmogenic activity and Ca2+ overload, through the reduction
of ROS production and inhibition of Ca2+/calmodulin-dependent protein kinases II (CaMKII) [120].
A study by Chen et al. demonstrated the protective effect of resveratrol against apoptosis induced by
hypoxia in H9c2 cardiomyocytes. Resveratrol (20 µM) increased SIRT1 expression, leading to inhibition
of forkhead box protein O1 (FoxO1) expression and activity [121].
Several studies showed the cardioprotective role of resveratrol in cardiomyocytes exposed to
I/R injury. Pretreatment with resveratrol (20 µM) protected neonatal rat ventricular cardiomyocytes
from I/R-induced oxidative injury, apoptosis, necrosis and mitochondrial dysfunction through the
induction of SIRT1 which modulated MAPKs signaling [122]. Resveratrol was effective in attenuating
the cardiotoxicity induced by chemotherapeutic drugs, such as DOX and arsenic trioxide, and by
anti-retroviral agents, such as azidothymidine (AZT). Danz et al. observed that resveratrol (10 µM)
inhibited DOX-induced ROS generation and necrosis through the activation of SIRT1 pathway in
neonatal rat ventricular myocytes [123]. Similarly, Gao and colleagues reported that pretreatment
with resveratrol (3µM) attenuated the mitochondrial ROS generation, apoptosis and necrosis induced
by AZT in human primary cardiomyocytes [124]. Zhao et al. investigated the protective effect of
resveratrol against arsenic trioxide (As2O3)-induced cardiotoxicity in H9c2 cardiomyocytes. They
demonstrated that pretreatment with resveratrol (10 µM) reduced cells apoptosis and necrosis,
increased cell viability and inhibited the generation of ROS and the intracellular Ca2+ mobilization
induced by As2O3 [125].
Resveratrol was also able to protect primary cultures of neonatal rat cardiomyocytes against
HG-induced apoptosis through the AMPK pathway. Resveratrol (50 µM) inhibited apoptosis and
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ROS production and increased the activity of anti-oxidant enzymes [126]. Das et al. demonstrated
that the treatment of human and murine cardiomyocytes with resveratrol (100 µM) reduced the
iron-induced oxidative stress by decreasing the levels of free radicals. The authors observed that the
inhibition of oxidative stress was dependent on the increase of SIRT1 and on the reduction of FoxO1
expression [127].
Several studies investigated the in vitro effects of resveratrol derivatives. The effect of polydatin,
a resveratrol glucoside, against phenylephrine induced-cardiac hypertrophy was investigated in
neonatal rat cardiomyocytes. Polydatin (50 µM) induced an anti-hypertrophic effect by decreasing
ROS production and by inhibiting the RhoA/ROCK signaling pathway, that play a role in mediating
the development of cardiac hypertrophy and heart failure [128]. Recently, Feng et al. investigated the
effect of an analog of resveratrol, bakuchiol (BAK), a monoterpene phenol isolated from the seeds of
Psoralea corylifolia (Leguminosae), against the I/R-induced oxidative damage. Pretreatment with BAK
(1 µM), administered 5 min before I/R, protected isolated rat hearts from I/R through the activation of




Curcumin (1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is another polyphenol
compound and a member of the curcuminoid family. It is found in turmeric, a spice produced from
the rhizome of Curcuma longa [17].
Several studies investigated the protective effect of curcumin against the oxidative stress
in cardiomyocytes. Pretreatment of HL-1 cells with curcumin (5 µM) reduced Ang II-induced
cardiomyocytes hypertrophy, oxidative stress and apoptosis [130]. Kim et al. showed that the
curcumin (10 µM) pretreatment reduced the cardiotoxicity caused by TNF-α, peptidoglycan or H/R in rat
cardiomyocytes [131]. Curcumin also attenuated the I/R-induced toxicity through SIRT1 pathway [132].
Xu et al. analyzed the protective role of curcumin against A/R-induced mitochondrial injuries in rat hearts.
Curcumin (1 µM) restored the mitochondrial respiratory activity, inhibited the lipoperoxidation, protein
carbonylation and cells apoptosis [133]. Treatment of primary cultures of neonatal rat cardiomyocytes
with curcumin (10 µM) reduced the glucose-induced toxicity by decreasing the apoptotic rate and
ROS production. Curcumin reduced the toxicity through the NADPH-mediated oxidative stress and
PI3K/Akt pathway [134].
Several studies investigated the cardioprotective effects of curcumin derivatives. Nehra et al.
evaluated the effect of nanocurcumin after hypoxia. H9c2 cardiomyocytes treated with nanocurcumin
(50 µM), compared to cells treated with curcumin, showed reduced hypertrophy and apoptosis [135].
In addition, nanocurcumin (50 ng/mL) inhibited the hypertrophy, reduced necrosis and ROS
generation, restored the mitochondrial membrane potential and glucose transporters and increased
ATP levels in primary human ventricular cardiomyocytes (HVCM) [136]. The treatment of hearts with
AID (alpha-interacting domain of the L-type Ca2+ channel) peptide tethered nanoparticles containing
25 mg of curcumin (NP-C-AID) or resveratrol (NP-R-AID) reduced cells necrosis, ROS generation
and mitochondrial membrane potential in response to I/R injury. However, only NP-C-AID reduced
the oxidative stress by balancing the GSH/GSSG ratio, and the muscle damage [137]. The effects of
monocarbonyl analogues of curcumin (MACs) with high stability was evaluated in I/R-induced toxicity
and injuries. Among these MACs, the curcumin analogue 14p (10 µM) reduced the toxicity by blocking
the oxidative stress, apoptosis and by activating the Nrf2 pathway in H9c2 cardiomyocytes [138].
3.5.2. Olive Oil Polyphenols
Olive oil is a source of at least 30 phenolic compounds. The three phenolic compounds found in
highest concentration in olive oil are oleuropein, hydroxytyrosol and tyrosol [139].
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Bali et al. compared the effects of the ethanolic and methanolic extracts of olive leaves with the
effects of oleuropein, hydroxytyrosol, and quercetin, as a positive control, in H9c2 cardiomyocytes
exposed to 4-hydroxy-2-nonenal (HNE), which induced oxidative damage. H9c2 cardiomyocytes were
pretreated with each compound (0.1, 10 µg/mL) and then exposed to HNE. Both extracts of olive
leaves and the other compounds inhibited cells apoptosis, blocked ROS production, counteracted
mitochondrial dysfunction. The ethanolic extract, that contained large amounts of oleuropein,
hydroxytyrosol, verbascoside, luteolin, and quercetin, exerted a better protection against HNE-induced
cardiotoxicity than the methanolic extract or each phenolic compound [140].
3.5.3. Salvianolic Acid
Salvianolic acid B (SalB), derived from the Chinese herb Salvia miltiorrhiza, was investigated
against TNF-α-induced MMP-2 up-regulation and oxidative stress in human aortic smooth muscle
cells (HASMCs). Pretreatment with SalB (0.1, 1, 10 µM) inhibited the TNF-α-induced increase of ROS
production. In addition, the polyphenol suppressed the TNF-α-induced MMP-2 enzymatic activity [141].
SalB (5, 10 µM) was also able to protect human aortic endothelial cells (HAECs) from oxidized-low
density lipoprotein (ox-LDL) induced oxidative injury via inhibition of ROS production [142].
3.5.4. Silymarin and Silibinin
Silymarin (SM) is a standardized extract from the seeds of Silybum marianum L. Gaertneri,
and the main constituents are silibinin, and other flavonolignans (dehydrosilibinin, silychristin
and silydianin). Silymarin (0.50 mg/mL) showed ROS radical scavenging activities. Silymarin
(0.50 mg/mL) improved mitochondrial functions, reduced NO levels, protein carbonyl content and
lipid peroxidation and increased anti-oxidant and Kreb’s cycle enzymes in cardiac mitochondria
exposed to copper-ascorbate [143].
Silibinin (50–200 µM) reduced cellular damage after H2O2-exposure in H9c2 cardiomyocytes.
In addition, the treatment with silibinin (100–200 µM) inhibited MAPKs and Akt activation in
phenylephrine-induced hypertrophic H9c2 cardiomyocytes [144]. Gabrielova et al. demonstrated that
the treatment of rat neonatal cardiomyocytes with 2,3-dehydrosilybin (DHS) (10 µM) attenuated the
H/R-induced damage by decreasing the generation of ROS and protein carbonyls [145].
3.6. Combination of Polyphenols and Comparative Studies
Esmaeili and Sonboli demonstrated the anti-oxidant and free radical scavenging activities of
Salvia brachyantha extract, which contains phenolic and flavonoid compounds such as rosmarinic acid,
caffeic acid, luteolin, gallic acid, rutin and catechin. The pretreatment of H9c2 cardiomyocytes with
the Salvia brachyantha extract (50–100 µg/mL) reduced the production of ROS, increased anti-oxidant
enzymes and prevented cells apoptosis induced by xanthine/XO [146].
Chen et al. analyzed the cardioprotective role of the total flavonoids from Clinopodium chinense
(Benth.) O. Ktze (TFCC), against the adverse effects of DOX treatment in H9c2 cardiomyocytes. H9c2
cardiomyocytes treated with TFCC (25 µM) showed increased levels of anti-oxidant enzymes and
decreased cells necrosis and apoptosis and ROS production. Furthermore, TFCC blocked DOX-induced
over-expression of p53 and regulated the phosphorylation of MAPKs, Akt and PI3K [147].
Chang et al. evaluated and compared the oxidant scavenging capacity of five flavonoids
(wogonin, baicalin, baicalein, catechin and procyanidin B2) and their protective efficacy in a chick
cardiomyocytes model. Catechin and procyanidin B2 showed the best scavenging capacity for DPPH
(1,1-diphenyl-2-picryhydrazyl) and superoxide radicals. Only baicalein exhibited a significant hydroxyl
radical scavenging potency. The cardiomyocytes were treated with three different treatment protocols
during I/R. The cardiomiocytes were exposed to flavonoids (25 µM) before and during I/R (chronic
treatment) or during I/R or during reperfusion phase. The administration of all flavonoids, except for
wogonin, reduced apoptosis in chronic treatment. Baicalein, procyanidin B2, and catechin reduced
apoptosis when flavonoids were administered only during I/R. In addition, only baicalein and
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procyanidin B2 treatment during reperfusion phase reduced cells apoptosis. Flavonoids had different
radical scavenging capacities and protective effects against I/R injury depending on the timing of
treatment [148].
Akhlaghi et al. analyzed the effects of several flavonoids (all at 25 µM) in H9c2 cardiomyocytes
exposed to I/R injury. The pretreatment with catechin improved cells viability, while cyanidin showed
a mild protection. However, only the pretreatment of H9c2 cardiomyocytes with quercetin and EGCG
reduced the oxidative stress [149].
Mechanisms of action of in vitro effects of polyphenols to counteract the oxidative stress-induced
cardiotoxicity are summarized in Table 1.
4. Bioavailability of Polyphenols: Is the Effective Polyphenols Dose Feasible In Vivo?
Although in vitro studies reported that polyphenols exert strong anti-oxidant activity, their
beneficial effects in humans remains poor, because of their low bioavailability. Bioavailability is the
quantity of a compound that is absorbed and metabolized within the human body after dietary intake
and it is measured commonly with the maximum plasma concentration (Cmax) reached after the
intake. In fact, in order to produce in vivo effects, a compound must enter the circulation and reach
the tissues, in the native or metabolized form, in a sufficient dose to exert biological activity [17].
After dietary intake, polyphenols are metabolized and then the metabolites induce the physiological
effects observed in in vivo models [150,151]. The doses of polyphenols employed in vitro usually
range between µmol/L and mmol/L, but the concentrations of metabolites in the plasma are of only
nmol/L [150]. Endogenous factors affect the bioavailability of polyphenols, such as their metabolism
in the gastrointestinal tract and liver, their binding on the surfaces of blood cells and microbial flora in
the oral cavity and gut, and regulatory mechanisms that prevent the toxic effects of high polyphenols
levels on mitochondria or other organelles [152]. Furthermore, polyphenols are often used as aglycones
or conjugates to sugar and not as their active metabolites in in vitro studies [150].
Polyphenols can interact with several substances that influence their bioavailability. For example,
polyphenols can bind proteins and metal cations that modify their absorption [153]. Dietary factors can
affect the bioavailability of polyphenols, such as food matrix and food preparation techniques [154].
The rate and extent of intestinal absorption and the metabolites in the plasma mainly depend on
the chemical structure of polyphenols. Polyphenols show different bioavailability and it has been
estimated that the plasma concentration of polyphenols and total metabolites reached after an intake of
50 mg of aglycones ranged from 0 to 4 µM. In addition, the half-lives of polyphenols in human plasma
are in the range of few hours and depend on the food source [155]. However, in order to assess the real
in vivo potential of polyphenols it is essential to know not only their plasma concentration, but the
concentration of the active metabolites in the target tissues [155]. Thus, it would be necessary to employ
the active metabolites of polyphenols in in vitro studies [151]. Accordingly, although it is very difficult,
it would be important to analyze the concentration of polyphenols in a specific tissue [150]. A limited
number of studies detected the concentration of polyphenols in different tissues of mice and rats,
including endothelial cells and heart, after administration of the compounds. The tissue concentrations
are different depending on the type of tissue and the dose administered, but tipically range from 30 to
3000 ng aglycone equivalents/g tissue [13]. Unfortunately, it is much more difficult to evaluate the
tissue concentrations of polyphenols in humans and in fact the studies are very scarce [150]. Overall,
a better knowledge of this issue is needed.
Despite the limit of the in vitro studies, anti-oxidative effects of polyphenols have been reported
in in vivo experimental models.
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Table 1. In vitro protective effects of polyphenols against the oxidative stress-induced cardiotoxicity.







↓ Apoptosis, ROS, LDH release
↓ DNA fragmentation
↓ Bid, p53 and NADPH oxidase
↓ ERK1/2, Akt, p38, JNK, TNF-α
↓ Phospho-ERK1/2 and –Akt
↑ Phospho-c-Jun and -PKCε
↓ ∆ψm loss and Ca2+
↓ Phospho-MAPKAPK-2 and caspase 3
[45,48,52,53,57]
3′-O-methyl quercetin H2O2 H9c2 cells ↓ Apoptosis and LDH release [45]
Hydroxytyrosol Xanthine/XO H9c2 cells ↑ Phopsho-ERK1/2 and -Hsp-27↓ Phospho-c-Jun [57]
Taxifolin Ang II Neonatal rat cardiomyocytes ↓ ROS and hypertrophy [56]
Rhamnetin H2O2 H9c2 cells
↓ Apoptosis and ROS
↑ CAT and MnSOD
↓ Phospho-Akt/GSK-3β, -ERK1/2, -p38 and -JNK
[46]
Isorhamnetin DOX H9c2 cells
↓ Apoptosis and ROS
↓ LDH release and lipid peroxidation
↑ Anti-oxidant markers
↓ Bax/Bcl-2 ratio, p53, caspases 9 and 3, PARP and cytochrome c release
↓ Phospho-ERK, -p38 and -JNK
[49]
Dihydromyricetin DOX Primary myocardialH9c2 cells
↓ Apoptosis and ROS
↑ GSH






↓ Apoptosis and ROS
↓ LDH release
↑ SIRT1, ∆ψm and Bcl-2
↓mPTP opening and DNA fragmentation
↓ Phospho-ERK1/2
↓ p53, cytochrome c release, and caspase 3 and PARP cleavage
[50,54]
3′,4′-dihydroxyflavonol I/RH2O2
Cardiomyocytes ↓ Superoxide↑ Phospho-ERK, -MEK and -Akt [47,55]
Apigenin A/R H9c2 cells ↓ Apoptosis and ROS↓ LDH release and cytochrome c release [58]
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Table 1. Cont.
Polyphenol Cardiac DamageInducers Cell Type In Vitro Effects Ref.
Apigenin glucoside,
vitexin A/R Neonatal rat cardiomyocytes
↓ Apoptosis and ROS










↓ Apoptosis and ROS
↓ LDH release














↓ Apoptosis and ROS
↓ Cellular damage and citosolic Ca2+
↓ LDH release and MDA formation
↑MnSOD, CAT and GSH-Px
↑ HO-1 and caveolin-1
↓ β-catenin, N-cadherin and Cx43
↓ p53, p21, caspase 3 and FasR
↓ STAT-1 activation, telomere attrition and TRF2 loss
[65–70,72,75,76]
EGCG and TF3 H2O2 Neonatal rat cardiomyocytes
↓ Cellular damage
↑ Akt, ERK1/2 and p38 MAPK [65]
(−)-epicatechin,









↓ Apoptosis and ROS
↑ NO and GSH-GSSG ratio
↓ ∆ψm loss and DNA fragmentation
↑ Contractile activity
[71,73]
Malvidin I/R Rat cardiomyocytes ↑ LV pressure, Akt, eNOS, ERK1/2, and phospho-GSK3β [78]
Cyanidin-3-O-glucoside I/R Rat cardiomyocytes ↓ Apoptosis and LDH release [79]
Blueberry phenol
fractions NE Adult rat cardiomyocytes
↓ Apoptosis and calpains
↑ SOD and CAT [80]
Narigenin H2O2 H9c2 cells
↓ Apoptosis and lipid peroxidation
↑ GSH-Px, GST, CAT, Nrf2, GCL and NQO-1 [81]
Naringin High glucose H9c2 cells
↓ Apoptosis and ROS
↑ GSH-Px, SOD, CAT and Bcl-2
↓ ∆ψm loss, p53, Bax, Bad, caspase, release of cytochrome c
↓ ERK1/2, p38 MAPK, JNK and leptin
[82–85]
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Table 1. Cont.
Polyphenol Cardiac DamageInducers Cell Type In Vitro Effects Ref.
Naringenin-7-O-glucoside DOX H9c2 cells
↓ Apoptosis and ROS
↑ SOD, CAT, GSH-Px and NQO-1
↓ CK, LDH, caspase 9 and 3 mRNA
↑ ERK, Nrf2, HO-1 and Bcl-2
[86–88]
Hesperetin LPS H9c2 cells
↓ Apoptosis
↑ Bcl-2
↓ Bax and phopsho-JNK
[89]
Puerarin Ang II Neonatal murinecardiomyocytes
↓ ROS
↓ NADPH oxidase
↓ ERK 1/2, JNK and AP-1
[90]
Calycosin H2O2 H9c2 cells
↓ Apoptosis
↑ ERα/β and Akt [91]
Licochalcone D I/R Rat cardiomyocytes
↓ Caspase 3 and PARP
↓ IL-6, TNF-α, CRP, LDH, CK, MDA, NO, NF-κB and p38 MAPK
↑ SOD, GSH/GSSG ratio, eNOS and Akt
[92]
Isoliquiritigenin I/R Cardiomyocytes ↓ ROS and mitochondrial potential↑ AMPK and ERK [94]
Safflor yellow A A/R Neonatal rat cardiomyocytes ↓ LDH, CK, MDA and Bax↑ SOD, CAT, GSH, GSH-Px and Bcl-2 [95]
Hydroxysafflor yellow A A/R H9c2 cells ↓ Apoptosis↑ Nrf2 [96]
Chalcone derivative
L6H9 Glucose H9c2 cells
↓ ROS, Hypertrophy and fibrosis
↓ Bax, caspase 9 and 3
↓ IL-6, TNF-α, COX and NF-κB
↑ Nrf2, HO-1, NQO-1 and GCLC
[97]
Aspalathin Hyperglycemia H9c2 cells
↓ ROS
↓ DNA nick and ∆ψm loss
↑ GSH, SOD and Bcl-2/Bax ratio
[99]
GLG H2O2 H9c2 cells
↓ Apoptosis, ROS and hemolysis
↓ Caspase 3 and nuclear condensation and fragmentation [100]
CSM-bark extract H2O2 Neonatal cardiomyocytes ↓ Apoptosis and ROS [101]
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Table 1. Cont.
Polyphenol Cardiac DamageInducers Cell Type In Vitro Effects Ref.
Hispidin H2O2 H9c2 cells
↓ Apoptosis, ROS and LDH release
↓ DNA fragmentation, caspase 3 and Bax
↑ HO-1, CAT, Bcl-2, Akt/GSK3β and ERK 1/2
[102]
Methyl gallate H2O2 Neonatal rat cardiomyocytes
↓ Apoptosis and ROS
↓ DNA damage, caspase 3 and ∆ψm loss
↑ GSH
[103]
Pyrrolidinyl caffeamide H2O2 HL-1 cells
↓ Apoptosis and ROS
↑ CAT, MnSOD, HO-1 and phospho-Akt [104]
Ferulic acid High glucose Cardiomyocytes ↓ Apoptosis and ROS↑ GSH, Nrf2, HO-1 and Keap-1 [105]
MPE Malathion H9c2 cells ↓ ROS, DPPH, ABTS and NO↑ Integrity of extra cellular matrix components [106]
Hydroxycinnamic acids DOX Neonatal rat cardiomyocytes ↓ Cellular damage and lipid peroxidation [107]
Danshensu I/R H9c2 cells ↓ Apoptosis, ROS, LDH release, CK, MDA and caspase 3↑ SOD, CAT, GSH-Px, HO-1, Bcl-2/Bax ratio, PI3K/Akt and ERK1/2 [108,109]
Sch B I/R H9c2 cells
↓ Apoptosis, inflammation and ROS
↓ Bax/Bcl-2 ratio, NF-κB
↑ ERK and Nrf2
[110,111]
Syringaresinol I/R H9c2 cells ↓ ROS, MDA, Bax/Bcl-2 ratio, caspase 3 and HIF-1↑ FoxO3 and anti-oxidant markers [113]
Sesamin DOXAng II H9c2 cells
↓ Apoptosis, ROS and MDA
↓ Caspase 3, p47phox and ∆ψm loss













Human and rat primary
cardiomyocytes
↓ Apoptosis, necrosis, autophagy, mitochondrial dysfunction and cell injury
↓ ROS, NADPH oxidase, LDH release, FoxO1, CaMKII
↓ Bax, phospho-p38 and -JNK
↑ SIRT1, Bcl-2, phospho-Akt and -ERK
↑ SOD, CAT
[116–127]
Polydatin Phenylephrine Neonatal rat cardiomyocytes ↓ ROS and RhoA/ROCK [128]
Bakuchiol I/R Rat cardiomyocytes ↓ Apoptosis↑ SIRT1, SDH, cytochrome c oxidase and SOD [129]
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Table 1. Cont.








↓ Apoptosis, ROS, NADPH oxidase, MDA, lipid peroxidation and protein
carbonylation
↓ Bax, cytochrome c and cardiolipin release, FoxO1, TLR2 and MCP-1
↑ Bcl-2, SDH, COX, SOD, SIRT1, Akt and phospho-GSK-3β
[131–134]
Nanocurcumin Hypoxia H9c2 cellsHVCM
↓ Apoptosis, hypertrophy and ROS
↓ HIF-1α, caspase 3 and 7, p53 translocation
↓ AMPKα, p-300 HAT, LDH, acetyl-CoA and ∆ψm loss
↑ c-Fos, c-Jun and ATP
[135,136]
Curcumin analogue 14p I/R H9c2 cells ↓ Apoptosis, ROS and MDA↑ Nrf2, SOD [138]
Salvianolic acid B TNF-α HASMC ↓ ROS, NADPH oxidase, MMP-2 [141]
Silymarin Copper-ascorbate Neonatal rat cardiomyocytes ↓ ROS, NO, protein carbonylation and lipid peroxidation↑mitochondrial function, GSH, GSH-Px, GR, SOD, PDH [143]
Silibinin H2O2Phenylephrine H9c2 cells
↓ Apoptosis, DNA damage, ROS
↓ ERK and Akt [144]
2,3-dehydrosilybin H/R Neonatal rat cardiomyocytes ↓ ROS, protein carbonylation and LDH release [145]
TFCC DOX H9c2 cells
↓ Apoptosis, ROS, MDA and LDH release
↓ DNA fragmentation, caspase 3, cytochrome c release, Bax/Bcl-2 ratio, p53,
phospho-ERK, -p38 and -JNK
↑ SOD, CAT, GSH-Px, phospho-Akt and PI3K
[147]
Abbreviations: ↑: increase; ↓: decrease; DOX: doxorubicin; H2O2: hydrogen peroxide; A/R: anoxia/reoxygenation; XO: xanthine oxidase; ROS: reactive oxygen species; ERK: extracellular
signal-regulated kinase; JNK: c-jun N-terminal kinase; TNF-α: tumor necrosis factor-α; PKCε: Protein kinase C epsilon type; ∆ψm: mitochondrial membrane potential; LDH: lactate
dehydrogenase; MAPKAPK-2: mitogen-activated protein kinase-activated protein kinase 2; Hsp: heat shock protein; Ang II: angiotensin II; CAT: catalase; MnSOD: manganese
superoxide dismutase; GSH: glutathione; SIRT1: sirtuin 1; mPTP: mitochondrial permeability transition pore; I/R: ischemia/reperfusion; CK: creatin kinase; H/R: hypoxia/reoxygenation;
hESC-CMs: human embryonic stem cells-derived cardiomyocytes; Nrf2: nuclear factor erythroid 2-related factor 2; HO-1: heme oxygenase-1; EGCG: (−)-epigallocatechin-3-gallate; MDA:
malondialdehyde; GSH-Px: glutathione peroxidase; TF3: theaflavin-3,3′ digallate; BSO: buthionine-(S,R)-sulfoximine; NO: nitric oxide; GSSG: glutathione disulfide; LV: left ventricular;
NE: norepinephrine; GCL: glutamate cysteine ligase; NQO-1: NAD(P)H:quinone oxidoreductase 1; LPS: lipopolysaccharide; ER: estrogen receptor; IL: interleukin; CRP: C reactive protein;
eNOS: endothelial nitric oxide synthase; COX: cycloxygenase; GCLC: glutamate cysteine ligase catalytic subunit; GLG: Gui-ling-gao; CSM: Castanea Sativa Mill.; MPE: gallic acid-enriched
methanolic Syzygium cumini pulp extract; DPPH: 1,1-diphenyl-1-picrylhydrazyl; ABTS: 2,2′-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid); Sch: schisandrin; HIF-1: hypoxia inducible
factor-1; FoxO: Forkhead box protein O; T-AOC: total antioxidant capacity; AZT: azidothymidine; As2O3: arsenic trioxide; CaMKII: Ca2+/Calmodulin-dependent protein kinases II; GR:
glutathione reductase; GST: glutathione s-transferase; TLR2: Toll-like receptor 2; MCP-1: monocyte chemoattractant protein; SDH: succinate dehydrogenase; HVCM: primary human
ventricular cardiomyocytes; HASMC: human aortic smooth muscle cells; MMP: metalloproteinase; PDH: piruvate dehydrogenase; TFCC: Clinopodium chinense (Benth.) O. Ktze.
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5. In Vivo Effects of Polyphenols Against Oxidative Stress-Induced Cardiotoxicity
5.1. Flavonoids
5.1.1. Flavonols
Several studies showed the in vivo cardioprotective effects of flavonols against DOX-induced
cardiotoxicity. The quercetin (100 or 15 mg/kg) pretreatment of mice and rats treated with DOX
improved cardiac function, blocked ROS generation and lipid peroxidation and increased anti-oxidant
enzymes [48,156]. Isorhamnetin (5 mg/kg, i.p.), kaempferol (10 mg/kg, i.p.) and dihydromyricetin
(125–500 mg/kg) administration reduced cardiomiocytes necrosis and apoptosis, ROS production and
lipid peroxidation and increased the production of anti-oxidant enzymes in in vivo models exposed to
DOX [49–51].
Flavonols effects were analyzed also in rats underewent I/R injury. Rats treated with kaempferol
(15 mM) recovered cardiac function, reduced infarct size and cardiomyocytes apoptosis [157].
Astragalin (kaempferol-3-O-glucoside) pretreatment (10 µM) showed cardioprotective effects in
rats via its anti-oxidative, anti-apoptotic, and anti-inflammatory activities [158]. The in vivo effects
of 3′,4′-dihydroxyflavonol (DiOHF) was investigated in sheep. The in vivo administration of DiOHF
(5 mg/kg) after I/R injury reduced ROS generation, neutrophil accumulation in coronary microvessels,
left ventricular diastolic pressure (LVDP) and infarct size, increased the left anterior descending
(LAD) coronary artery blood flow, the total plasma nitrate and nitrite and restored the myocardial
function [55]. The myocardial I/R injury was blocked by NP202, a novel pro-drug of DiOHF, through
the activation of MAPKs signaling in sheep [47].
A study by Bhandary et al. investigated the preventive effects of rutin, quercetin and various
isoflavones (biochanin A, daidzein, genistein) in an ex vivo model of I/R injury. They perfused rat
hearts with isoflavones (10 µM), quercetin (10 µM), and rutin (50 µM) before ischemia and during the
reperfusion time. Only rutin possessed the ability to attenuate cardiac I/R-associated hemodynamic
alterations [159]. In addition, rutin increased anti-oxidant molecules and reduced cells necrosis and
apoptosis and overall cardiac dysfunction in rats exposed to sodium fluoride-induced oxidative
stress [160].
The isoproterenol injection induced cardiotoxicity in rats. The co-treatment with vincristine
(25 mg/kg) and quercetin (10 mg/kg) attenuated the cardiotoxicity induced by isoproterenol [161].
Guo et al., employing a mouse model with transverse aortic constriction (TAC), demonstrated
that taxifolin, a dihydroquercetin derivative decreased ROS levels, attenuated the pressure overload,
blocked the cardiac remodeling, ventricular dysfunction and fibrosis [56].
5.1.2. Flavones
Several studies demonstrated the in vivo cardioprotective role of flavones against I/R. In murine
and rat models baicalein (30 mg/kg), apigenin (5 mg/kg) and vitexin (6, 3, 1.5 mg/kg) reduced I/R
injury-induced infarct size, apoptosis, pro-inflammatory cytokines and oxidative stress [162–164].
Employing diabetic rats subjected to myocardial I/R, it has been assessed the protective effects of
luteolin or breviscapine, a flavonoid extracted by Erigeron breviscapus. Luteolin (100 mg/kg/day
intragastrically) or breviscapine (60 mg/kg orally) reduced the ROS production [165,166]. Luteolin
also improved left ventricular function and cardiac tissue viability [165]. In addition, breviscapine
reduced the expression of ICAM-1 in rat myocardium, the inactivation of ATPase and associated ionic
disturbances [166].
The protective effect of apigenin in isolated rat heart suffered from A/R was also demonstrated. Rats
intraperitoneally injected with apigenin (4 mg/kg) showed reduced cells death and infarct size [58].
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5.1.3. Flavan-3-Ols
Several studies reported that the administration of green tea extract (GTE) (200 mg/kg or
400 mg/kg, prior to I/R injury) to rats reduced the myocardium damage, infarct size and apoptosis
and increased the anti-oxidant enzymes [167,168]. The anti-oxidant properties of flavan-3-ols were
also evaluated in DOX-exposed in vivo models. Oral pretreatment for 30 days with GTE (100, 200 and
400 mg/kg) or procyanidins (150 mg/kg daily) decreased the cardyomyocytes death and increased
anti-oxidant enzymes in rat models exposed to DOX [169,170].
Sheng et al. reported the protective effects of EGCG in cardiac hypertrophy induced by abdominal
aortic constriction in rats. They showed that EGCG (50 and 100 mg/kg) administered intragastrically
to rats for 6 weeks, decreased myocardium damage and ROS generation. The highest doses of EGCG
improved histological changes in the heart tissue, inhibited fibrosis and myocytes apoptosis [67]. Using
the same rat model, the authors evaluated the effect of EGCG and other traditional anti-hypertrophic
therapeutic agents on telomere dysfunction mediated apoptotic signal. They demonstrated that
treatment for 6 weeks with EGCG (50 and 100 mg/kg) or quercetin (100 mg/kg) reduced heart weight
indices and cardiac myocytes apoptosis in the hypertrophic myocardium [171].
Another investigation reported the effect of grape seed proanthocyanidins (GSP) against cadmium
(Cd), a toxic heavy metal that induced oxidative stress and cardiotoxicity. In this study, GSP pretreatment
(100 mg/kg) reduced Cd-induced disruption of cardiac myofibrils, cardiomyocytes necrosis and apoptosis,
production of pro-inflammatory cytokines and increased the levels of anti-oxidant enzymes in rats [172].
Wang et al. demonstrated that GSP (195 mg/kg, intragastric administration) treatment prevented
deoxycorticosterone (DOCA)-salt-induced cardiovascular remodeling and endothelial dysfunction in
mice, in part through the involvement of oxidative stress [173].
5.1.4. Anthocyanins
Liu et al. reported the effects of blueberry anthocyanins-enriched extracts (BAE) on cyclophosphamide
(CTX)-induced cardiac toxicity in rats. BAE (20 and 80 mg/kg daily by gavage) treatment attenuated the
CTX-induced cardiac injury through its anti-inflammatory and anti-oxidant proprieties. BAE decreased
mean arterial blood pressure and myocardial leukocyte infiltration, increased heart rate and improved
cardiac dysfunction, and reduced LV hypertrophy and fibrosis. Rats treated with BAE showed a
decrease expression of pro-inflammatory cytokines, an increase of anti-inflammatory cytokines and
anti-oxidant enzymes [174].
5.1.5. Flavanones
Two studies reported the cardioprotective role of the flavanone glycoside hesperidin on
I/R-induced arrhythmias in an in vivo rat model. Rats were administered with hesperidin (100 mg/kg,
p.o. for 15 days) and then subjected to I/R. The administration of hesperidin induced antiarrhythmic
effects, a reduction of inflammation, oxidative stress and cardiomyocytes apoptosis [175,176]. A similar
study was conducted with naringin. Naringin was administered per os (40, 80 mg/kg, daily) to rats
for 14 days and then I/R injury was induced by coronary artery occlusion. Naringin restored I/R
injury, as demonstrated by the normalization of cardiac injury markers, by the increased activity of
anti-oxidant enzymes, by the reduction of cells apoptosis, infarct size and inflammation [177].
The protective effect of hesperetin against DOX-induced oxidative stress and DNA damage was
analyzed in rat heart. Rat, treated with DOX and hesperetin (50 and 100 mg/kg b.w., p.o. by gavage for
5 consecutive days in a week), showed decreased ROS production and cells apoptosis [178]. Hesperetin
(30 mg/kg, p.o.) and hesperidin (200 mg/kg, p.o.) administration to murine and rat models inhibited
the cardiac remodeling and fibrosis, oxidative stress and apoptosis induced by pressure overload and
isoproterenol [179,180].
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In addition, Elavarasan et al. also demonstrated that the anti-oxidant activity of hesperidin
protected cardiac tissue of aged rats against age-related increase in oxidative stress. Hesperidin
(100 mg/kg/day, p.o. for 90 days) increased the activity of anti-oxidant enzymes [181].
The cardioprotective role of hesperidin and naringin on hyperglycemia-induced oxidative damage
in HFD/streptozotocin (STZ)-induced diabetic rats has been reported by Mahmoud et al. Diabetes
was induced and then rats were treated with hesperidin or naringin (50 mg/kg, p.o.) daily for 4 weeks.
Oral administration of hesperidin and naringin prevented diabetic complications and increased the
activities of anti-oxidant enzymes in experimental diabetic rats [182].
5.1.6. Isoflavones
In vivo effects of calycosin-7-O-β-D-glucoside (CG) on I/R injury were investigated by Ren et al.
Pretreatment of rats with CG (30 mg/kg i.v.) 30 min before the ligation of the left anterior descending
(LAD) coronary artery was able to improve cardiac function, to decrease infarct size and to enhance
the activity of SOD. CG alleviated I/R injury through the activation of the PI3K/Akt pathway and the
inhibition of apoptosis [183].
Gang et al. investigated the in vivo effect of puerarin in Ang II-induced cardiac hypertrophy.
Puerarin (100 and 200 mg/kg, gavage) reduced cardiac hypertrophy induced by Ang II in mice [90].
The effect of puerarin on severe burn-induced acute myocardial injury in rats was assessed by
Liu et al. Groups of adult Wistar rats were subjected to a 30% TBSA (total body surface area) full-thickness
dermal burn and resuscitated with an intraperitoneal injection of 4 mL/kg/TBSA of lactated Ringer’s
solution with or without puerarin (10 mg/kg). Results showed that puerarin protected cardiomyocytes
from severe burn-induced ultrastructural modifications and death [184].
5.1.7. Chalcones and Dihydrochalcones
Zhong et al. evaluated the in vivo effects of the chalcone derivative L6H9 against STZ-induced
diabetes in C57BL/6 mice. L6H9 (20 mg/kg by gavage) protected multiple organs in diabetic mice.
In particular, the heart of mice treated with L6H9 did not show structural abnormalities and fibrosis.
These mice showed lower levels of ROS, cytokines, and apoptosis [97].
Several studies investigated the in vivo effects of chalcones against I/R. Treatment with
licochalcone C (2.0 mM) increased LVDP, levels of anti-oxidant enzymes and decreased cardiomyocytes
mitochondrial injury, necrosis and apoptosis in rats [185]. Another study showed the effects of
intraperitoneal injection of Cl-chalcone (50 µg/kg) and F-chalcone (100 µg/kg) in albino rats with
I/R. Rat hearts treated with Cl-chalcone and F-chalcone showed limited infarct size and high levels of
anti-oxidant enzymes [186]. A study reported the protective effect of rooibos extract against myocardial
I/R injury. They showed that the aortic output recovery after reperfusion was improved in hearts
isolated from male Wistar rats supplemented with aqueous rooibos extract for 7 weeks when compared
to that supplemented with green tea (Camellia sinensis) extract [187].
5.2. Phenolic Acids
Ku et al. analyzed the response of pyrrolidinyl caffeamide (PLCA) against I/R-induced oxidative
stress in rats. PCLA administration (1 mg/kg i.p.) reduced the levels of troponin and lipid peroxidation,
improved cardiac functions and attenuated the myeloperoxidase (MPO) activity, a marker of neutrophil
accumulation [104].
Tang et al. investigated the effect of danshensu in spontaneously hypertensive rats (SHR).
Danshensu (10 mg/kg/day i.p.) decreased the HW/BW index, prevented the increase of blood pressure,
and reduced arrhythmias in rats exposed to I/R [188]. In addition, danshensu possessed a cardioprotective
effect against I/R injury when given to rats during reperfusion (30 and 60 mg/kg, for 3 h) [108].
The protective effects of the preparation Shenge, composed by 1:1 ratio of puerarin and danshensu,
has been evaluated on acute ischemic myocardial injury in rats. Rats were subjected to LAD coronary
artery occlusion and were injected intravenously with Shenge (30, 60, or 120 mg/kg b.w.) 15 min later.
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Shenge was able to improve electrocardiographic changes, the size of ischemic area and anti-oxidant
activities induced by the acute myocardial ischemia [189].
5.3. Lignans
Several studies analyzed the cardioprotective effects of Schisandrin (Sch) B against DOX-induced
oxidative stress. The administration of Sch B (25, 50 and 100 mg/kg) to mice and rats reduced
cardiomyocytes apoptosis and necrosis in left ventricle and the activity of MMPs induced by
DOX [190,191]. The pretreatment with Sch B (100 mg/kg) significantly increased the levels of GSH
redox cycling enzymes [190]. Su et al. also evaluated the in vivo effect of sesamin in DOX-induced
cardiotoxicity in rats. The treatment of rats with sesamin (20 mg/kg, orally, for 10 consecutive days)
reduced the DOX-induced toxicity through the normalization of the electrocardiography and the
decrease of histopathological changes [114]. Daily sesamin treatment (80 or 160 mg/kg, by gavage) in
SHR for 16 weeks improved LV hypertrophy and fibrosis. The treatment reduced the systolic blood
pressure, enhanced cardiac total anti-oxidant capabilities and TGF-β1 expression [192].
Chen et al., employing a mice model of myocardial infarction (MI) established by a permanent
ligation of the left anterior descending (LAD) coronary artery, reported that the MI mice treated with Sch
B (80 mg/kg) showed increased survival rate, improved heart function and decreased infarct size [111].
Chiu et al. demonstrated that Sch B also exerted a protective role against myocardial I/R injury
through the activation of ERK pathway in rats. Sch B (1.2 mmol/kg, intragastric) decreased LDH
leakage and increased GSH levels [110].
The effects of magnolol, extracted from Magnolia officinalis, deoxyschizandrin (DSD) and
schisantherin A (STA) was analyzed in rats subjected to I/R. Magnolol (10 mg/kg, i.p.), DSD
(40 µmol/kg, i.v.) and STA (40 µmol/kg, i.v.) reduced infarct size, arrhythmias and improved
I/R-induced myocardial dysfunctions [112,193].
5.4. Stilbenes (Resveratrol)
Resveratrol was able to prevent the development of oxidative stress in SHR. Treatment with
resveratrol (2.5 mg/kg b.w., daily, by oral gavage for 10 weeks) reduced ROS production [119].
Dolinsky et al. reported that resveratrol (2.5 mg/kg b.w., daily, by oral gavage for 2 weeks) reduced
the levels of cardiac HNE-protein adducts and the HNE adducts formation on liver kinase B1 (LKB1),
leading to a reduction of left ventricular hypertrophy [194].
Zhao et al. investigated the effect of resveratrol in a mouse model of arsenic trioxide (As2O3)-induced
cardiomyopathy in vivo. Pretreatment with resveratrol (3 mg/kg, i.v., on alternate days for three
days 1 h before As2O3 administration) attenuated As2O3-induced structural and electrocardiographic
abnormalities, increased increased anti-oxidant activity of mice treated with As2O3 [125].
Resveratrol exerted a beneficial effect in mice with diabetic cardiomyopathy induced by
strepozotocin (STZ). Mice fed with a diet enriched with resveratrol (60 and 300 mg/kg/day, for
16 weeks) showed an attenuation of oxidative injury, a decreased cardiomyocytes apoptosis and an
improved cardiac function. In addition, resveratrol increased the autophagic flux in diabetic mouse
hearts [195].
Das et al. reported that the oral administration of resveratrol reduced the myocardial injury
induced by iron. Mice treated with resveratrol decreased oxidative stress and myocardial fibrosis.
These responses were achieved by the increase in SIRT1 expression and the reduction in FoxO1
expression [127].
Resveratrol and polydatin, a resveratrol glucoside, attenuated DOX-induced cardiotoxicity in
rats. Resveratrol (10 or 15 mg/kg) reduced cardiac dysfunction, oxidative damage and apoptosis and
increased anti-oxidant enzymes [196,197]. In addition, a synergistic effect of polydatin and vitamin C
to reduce the cardiotoxicity of DOX was observed. The combined treatment (polydatin and vitamin C
both 200 µmol/kg) improved electrocardiography, reduced ROS production, increased anti-oxidant
activities, and improved the myocardial metabolism in rats [198].
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The treatment with resveratrol (20 mg/kg, s.c. or 5, 15, 45 mg/kg/day for 10 days, by gavage)
protected mice and rats against LPS and cisplatin-induced cardiotoxicity by restoring the intracellular
redox status [199,200]. The anti-hypertrophic effect of polydatin or isorhapontigenin, a resveratrol
analogue, was demonstrated in C57BL/6 mice subjected to transverse aortic constriction (TAC),
a model of pressure-overload-induced cardiac hypertrophy in vivo. Polydatin (50 mg/kg, daily by
gavage) reduced the TAC-induced cardiac hypertrophy [128].
5.5. Other Polyphenols
5.5.1. Curcumin
Several studies investigated the effect of curcumin in I/R. Curcumin exerts a cardioprotective
effect against I/R injury through the reduction of oxidative stress and mitochondrial dysfunction.
Curcumin pretreatment (200 mg/kg) reduced the loss of cardiac mechanical work, the lipid
peroxidation and the levels of inflammatory markers in rats [131,201]. In addition, curcumin reduced
the cardiotoxicity induced by I/R injury through the SIRT1 pathway. In fact, the in vivo pretreatment
of rats with curcumin increased the levels of SIRT1, anti-oxidant enzymes and reduced the cellular
damage and necrotic and apoptotic cells [132]. Li et al. showed that the administration of curcumin
analogue 14p (10 mg/kg) decreased the infarct size and myocardial apoptosis to the same extent
as the high dose curcumin (100 mg/kg) in a mouse model of myocardial I/R [138]. In another
study, the co-treatment of rats with curcumin (60 mg/kg) and isoprenaline reduced the percentage of
isoprenaline-induced apoptotic and necrotic cells and restored the levels of anti-oxidants. Curcumin
decreased the opening of mPTP induced by isoprenaline without modify mitochondria [202].
Diabetic cardiomyopathies are associated with high levels of membrane-bound protein kinase C
(PKC). Treatment of STZ-induced diabetic rats with curcumin (100 mg/kg/day for 8 weeks)
reduced cardiomyocyte hypertrophy, oxidative stress, myocardial fibrosis and left ventricular
dysfunctions [203].
Imbaby et al. analyzed the cardioprotective effects of curcumin and nebivolol against cardiotoxicity
induced by DOX therapy in rats. Oral administration of curcumin (200 mg/kg) attenuated DOX-induced
cardiotoxicity. The treatment increased survival rate and anti-oxidant enzymes, decreased lipid
peroxidation and histological alterations [204].
5.5.2. Olive Oil Polyphenols
In several studies, Andreadou et al. demonstrated the cardioprotective effect of oleuropein against
DOX. Oleuropein administration (100 or 200 mg/kg for 5 or 3 consecutive days) reduced cells damage
and necrosis in rats induced by DOX [205]. In addition, the same authors investigated the effect of
oleuropein in chronic DOX-induced cardiomyopathy in rats. The intraperitoneal administration of
oleuropein (1000 or 2000 mg/kg for 14 days) improved heart contractility, reduced apoptosis and
production of inflammatory cytokines, degenerative myocardial lesions and levels of nitro-oxidative
compounds [206].
5.5.3. Silymarin and Silibinin
Several studies analyzed the effect of silymarin against the cardiotoxicity induced by anti-cancer
drugs. Silymarin protected rats against DOX-induced injury. It has been observed that silymarin (50 or
100 mg/kg) reduced myocardial and renal damage and NO levels [207,208]. Silymarin treatment
(25, 50 or 100 mg/kg) reduced the serum levels of necrosis markers, enhanced anti-oxidant activities
and attenuated the damage of mitochondria in mice and rats exposed to cisplatin or acrolein [209,210].
The protective effect of silibinin against arsenic-induced oxidative stress has been analyzed in
rats. Silibinin administration (75 mg/kg) reduced the myocardial damage, the activity of heart
mitochondrial enzymes, levels of plasma and cardiac lipids, while it up-regulated the levels of
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anti-oxidant enzymes in hepatic tissues. Thus, silibinin attenuated the mitochondrial damage and
restored the heart function [211].
5.6. Combination of Polyphenols
Chen et al. evaluated the cardioprotection of flavonoids extracted from Clinopodium chinense
(Benth.) O. Ktze (TFCC) against DOX treatment in rats. TFCC (20, 40 and 80 mg/kg) treatment
induced the recovery of body and heart weights, balanced the levels of cardiac enzymes, inhibited
ROS production and apoptosis and up-regulated the level of anti-oxidant enzymes [147].
Table 2 summarizes molecular mechisms of in vivo effects of polyphenols against the oxidative
stress-induced cardiotoxicity.
Overall, Figure 3 shows the in vitro and in vivo effects of polyphenols in cardiovascular disease.
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Table 2. In vivo protective effects of polyphenols against the oxidative stress-induced cardiotoxicity.
Polyphenol In Vivo Model Protective Effects Ref.
Quercetin
Mice treated with DOX
↑ Cardiac function
↓ ROS and lipid peroxidation
↑ Bmi-1 and SOD expression
[48]
Rats treated with DOX
↓ Blood pressure and heart rate increase
↓ Cellular damage
↓MMP-2 activation and apoptosis
↑ SOD activity
[156]
Vincristine and quercetin Rats exposed to isoproterenol
↓ CK-MB, LDH, ALT, cTnT
↓ Lipid peroxidation
↑ SOD, CAT, GR, GSH-Px activities
↓ Heart rate and ST-segment elevation
[161]
Taxifolin Mouse model of TAC
↓ Pressure overload, fibrosis, ROS, MDA, HNE
↓ Cardiac remodeling and ventricular dysfunction
↓ ANP, BNP, β-MHC expression
↓ Phospho-ERK1/2, phospho-JNK1/2, Smad2
[56]
DiOHF Sheep model of I/R injury ↓ ROS, neutrophil accumulation, LVDP, infarct size↑Myocardial function [55]
Isorhamnetin Rats treated with DOX ↓ Cardiac enzymes, apoptosis, ROS, lipid peroxidation↑ Anti-oxidant enzymes [49]
Rutin Rats exposed to sodium fluoride
↓ Cardiac dysfunction, cardiac serum markers
↓ Lipid peroxidation and DNA fragmentation
↑ SOD, CAT, GSH levels
[160]
Dihydromyricetin Mice treated with DOX ↑ Survival rate↓ AST, CK-MB, LDH activities [51]
Kaempferol Rats treated with DOX
↑ Body and heart weights, SOD, CAT
↓ LDH levels, apoptosis, mitochondrial damage [50]
Rat model of I/R injury ↑ Cardiac function, SOD activity, GSH/GSSG ratio↓ CK, LDH, MDA levels, infarct size, apoptosis [157]
Astragalin Rat model of I/R injury ↑ Cardiac function, SOD activity, GSH/GSSG ratio↓ CK, LDH, MDA levels, infarct size, apoptosis [158]
Baicalein Murine model of I/R injury
↓ Infarct size, apoptosis, pro-inflammatory cytokines
↓ ROS, MDA levels
↑ GSH-Px
[162]
Apigenin Rat model of I/R injury ↓ Infarct size, apoptosis, CK, LDH, MDA levels↑ SOD [163]
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Table 2. Cont.
Polyphenol In Vivo Model Protective Effects Ref.
Vitexin Rat model of I/R injury
↑ Cardiac function, SOD activity
↓ Infarct size, apoptosis, inflammatory cytokines
↓ CK, LDH, MDA
[164]
Luteolin Rat model of I/R injury ↑ Cardiac function, MnSOD activity↓ LDH, MDA levels [165]
Breviscapine Rat model of I/R injury ↓ ICAM-1, ROS, MDA↑ SOD, GSH-Px activities [166]
Green Tea Exctract (GTE)
Rat model of I/R injury ↓ Infarct size, apoptosis↑ GSH, GCL, QR [167]
Rats treated with DOX ↓ AST, CK, LDH, lipid peroxidation↑ Cyt P450, GSH, GSH-Px, GR, GST, SOD, CAT [169]
EGCG, quercetin Rats with cardiac hypertrophy ↓ Systolic blood pressure, heart weight indices, MDA↑ SOD, GSH-Px activities, apoptosis [67,171]
GSP Rats treated with cadmium
↓ Cardiac damage, CK-MB, AST, ALT, ALP, LDH
↓ Pro-inflammatory cytokines, apoptosis
↑ GSH-Px, GR, GST, SOD, CAT, G6PD
[172]
Procyanidins Rats treated with DOX ↑ Cardiac function↓ Lipid peroxidation [170]
BAE Rats treated with CTX ↑ Cardiac function , IL-10, SOD, GSH↓ Apoptosis, pro-inflammatory cytokines, MDA [174]
Hesperidin Rat model of I/R injury ↑ Cardiac function↓ Apoptosis, oxidative stress [176]
Naringin Rat model of I/R injury ↓ CK-MB, LDH, apoptosis, infarct size, inflammation↑ SOD, GSH-Px [177]
Hesperetin Rats treated with DOX ↓MDA, DNA damage↑ GSH [178]
Hesperidin Rats treated with isoproterenol
↓ Lipid peroxidation
↓ CK, CK-MB, LDH, AST, ALT, cTnI, cTnT
↑ SOD, CAT, GSH-Px, GST, GR
[180]
Hesperidin, naringin HFD/STZ-induced diabetic rats
Prevention of diabetic complications
↓MDA, NO
↑ SOD, CAT, GSH-Px, GR
[182]
Nutrients 2017, 9, 523 27 of 43
Table 2. Cont.
Polyphenol In Vivo Model Protective Effects Ref.
Puerarin
Mice treated with Ang II ↓ Cardiac hypertrophy, HW/BW, LVW/BW [90]
Rats subjected to severe burn ↓ CK-MB, cTnT, MDA, MPO [184]
Calycosin-7-O-β- D -glucoside Rat model of I/R injury ↑ Cardiac function, SOD activity↓ Infarct size, CK, LDH, MDA, apoptosis [183]
Chalcone derivative L6H9 STZ-induced diabetic mice
↓ Cardiac damage and fibrosis
↓ ROS, TNF-α, IL-6, COX2, Bax
↑ HO-1, NQO-1, GCLC, Bcl-2
[97]
Licochalcone B Rat model of I/R injury ↓ Apoptosis, MDA, LDH, CK, TNF-α↑ LVDP, SOD, GSH/GSSG ratio [185]
Cl-chalcone, F-chalcone Rat model of I/R injury ↓ Infarct size, lipid peroxidation, MDA↑ SOD, CAT [186]
Pyrrolidinyl caffeamide (PLCA) Rat model of I/R injury ↓ Troponin, MDA, MPO↑ Cardiac function, CAT, HO-1, MnSOD [104]
Danshensu
I/R in spontaneously hypertensive
rats (SHR)
↓ Blood pressure increase, arrhythmias, HW/BW
↑ NO content, iNOS activity [188]
Rat model of I/R injury ↓ Infarct size, CK-MB, cTnI [108]
Shenge Rats subjected to LAD
↓ ST-segment elevation, infarct size
↓ CK-MB, LDH, MDA
↑ SOD activity
[189]
Schisandrin B (Sch B)
Rats treated with DOX
↓ CK, CK-MB, LDH, AST, MDA, MMP
↓ Cardiac damage, cell death
↑ GSH, GSH/GSSG, GR, GST, GSH-Px, SOD
[190]
Mice treated with DOX
↓ Cardiac damage, apoptosis, DNA damage
↓ ROS, MDA, TNF-α, IL-1β, IL-6, MMP-2, MMP-9
↑ GSH, LV performance
[191]
Mouse model of myocardial
infarction (MI)
↑ Survival rate, heart function, eNOS
↓ Infarct size, TGF-β1, TNF-α, IL-1β, Bax/Bcl-2 [111]
Rat model of I/R injury ↑ GSH↓ LDH [110]
Magnolol Rat model of I/R injury ↓ Infarct size, apoptosis, myocardial dysfunction [193]
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Polyphenol In Vivo Model Protective Effects Ref.
Sesamin
SHR rats
↓ Cardiac fibrosis, systolic blood pressure
↓ HW/BW, LVW/BW, MDA, TGF-β1
↑ Cardiac total anti-oxidant capability
[192]
Rats treated with DOX Normalization QT intervals, QRS complexes↑ SIRT1 activation, MnSOD [114]
Deoxyshizandrin (DSD) +
Schisantherin (STA) Rat model of I/R injury
↓ Infarct size, LVDP, arrhythmias, MDA
↑ LVSP, SOD [112]
Resveratrol
SHR rats ↓ H2O2, left ventricular hypertrophy↑ CAT activity [119,194]
Mice treated with arsenic trioxide
(As2O3)
↓ QT-interval prolongation, cardiac damage, LDH
↑ GSH-Px, CAT, SOD [125]
Mice treated with LPS ↑ SERCA2a, Nrf2↓MDA, HNE [199]
Rats treated with cisplatin ↓ LDH, CK, MDA↑ SOD, GSH, GSH-Px, CAT [200]
Rats treated with DOX ↓ Cardiac dysfunction, apoptosis, MDA, CK, LDH↑ SIRT1, GSH [196,197]
STZ-induced diabetic mice ↓ Apoptosis, p62↑ Cardiac function, SIRT1, autophagy [195]
Polydatin + vitamin C Rats treated with DOX ↓ ROS, MDA, CRP, ST and QT intervals↑ GSH-Px, SOD [198]
Polydatin Mice subjected to TAC ↓ Cardiac hypertrophy [128]
Curcumin
Rat model of I/R ↓ Lipid peroxidation↑ Cardiac function, SOD, CAT, GSH, GSH-Px [201]
Rats treated with isoprenaline ↓ Apoptosis, MPO, MDA↑ CAT, GSH [202]
Rat model of I/R ↑ SIRT1, Bcl-2, SDH, COX↓ Bax, CK, LDH [132]
STZ-induced diabetic rats ↓MDA, hypertrophy, fibrosis, ventricular dysfunction↑ GSH-Px [203]
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Table 2. Cont.
Polyphenol In Vivo Model Protective Effects Ref.
Curcumin + nebivolol Rats treated with DOX
↑ Survival rate, SOD, GSH-Px, Body and heart weights
↓ Cardiac damage, lipid peroxidation, NO
↓ QT and ST intervals
[204]
Oleuropein Rats treated with DOX ↓ CK, CK-MB, LDH, ALT, AST, apoptosis↓MDA, protein carbonyl, nitrotyrosine, iNOS [205,206]
Silymarin
Rats treated with DOX ↓ CK, LDH, creatinine, urea, MDA↑ GSH [207]
Rats treated with cisplatin ↓ LDH, CK, CK-MB, cTnI, MDA↑ GSH, SOD [209]
Mice treated with acrolein ↓ Lipid peroxidation, apoptosis, MDA, cTnI, CK-MB↑ GSH, SOD, CAT [210]
Silibinin Rats treated with arsenic
↑ Cardiac function, Nrf-2, HO-1
↑ SOD, CAT, GSH-Px, GST, GR, G6PD
↓ CK-MB, LDH, AST, ALT, ALP, HW/BW
[211]
Clinopodium chinense (Benth.)
O. Ktze (TFCC) Rats treated with DOX
↑ Body and heart weights
↓ CK, AST, LDH, MDA, apoptosis
↑ SOD, CAT, GSH-Px
[147]
Abbreviations: ↑: increase, ↓: decrease; DOX: doxorubicin; ROS: reactive oxygen species; SOD: superoxide dismutase; MMP: metalloproteinase; CK-MB: creatin kinase-MB; LDH: lactate
dehydrogenase; ALT: alanine aminotransferase; cTn: cardiac troponin; CAT: catalase; GR: glutathione reductase; GSH-Px: glutathione peroxidase; TAC: transverse aortic constriction;
MDA: malondialdehyde; HNE: 4-hydroxy-2-nonenal; ANP: atrial natriuretic peptide; BNP: brain natriuretic peptide; ERK: extracellular signal-regulated kinase; JNK: c-jun N-terminal
kinase; DiOHF: 3′,4′-dihydroxyflavonol; I/R: ischemia/reperfusion; LVDP: left ventricular end diastolic pressure; GSH: glutathione; AST: aspartate aminotransferase; GSSG: glutathione
disulfide; MnSOD: manganese superoxide dismutase; EGCG: (−)-epigallocatechin-3-gallate; IL: interleukin; GCL: glutamate cysteine ligase; QR: quinone reductase; Cyt: cytochrome; GST:
glutathione s-transferase; GSP: grape seed proanthocyanidins; ALP: alkaline phosphatase; G6PD: glucose-6-phosphate dehydrogenase; BAE: blueberry anthocyanins-enriched extracts:
CTX: cyclophosphamide; HFD/STZ: high fat diet/streptozotocin; Ang II: angiotensin II; HW/BW: heart weight/body weight ratio; LVW/BW: left ventricular weight/body weight ratio;
MPO: myeloperoxidase; TNF-α: tumor necrosis factor-α; COX: cyclooxygenase; HO-1: heme oxygenase-1; NQO-1: NAD(P)H:quinone oxidoreductase 1; GCLC: glutamate cysteine ligase
catalytic subunit; NO: nitric oxide; iNOS: inducible nitric oxide sinthase; LAD: left anterior descending; SHR: spontaneously hypertensive rats; SIRT1: sirtuin 1; LVSP: left ventricular
systolic pressure; SERCA: sarcoplasmic reticulum Ca2+ ATPase; Nrf2: nuclear factor erythroid 2-related factor 2; CRP: C reactive protein; SDH: succinate dehydrogenase.
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6. Evidence from Human Studies
Although human studies are not the main focus of this review and have been reviewed
elsewhere [153,212,213], a short section of results from clinical trials is reported. This section might help
to understand whether in vitro and in vivo results obtained in experimental models can be mimicked
in humans. Many human studies have investigated the potential effects of polyphenols, such as
cocoa-, olive-, tea-, grape-contained polyphenols, in cardiovascular diseases [212]. Recently, it has been
reported that resveratrol intake (10 mg resveratrol capsule, per day for 3 months) reduced LDL, platelet
aggregation and improved endothelial function and vasodilation in 40 patients with coronary artery
disease [214]. In another study, resveratrol (400 mg, daily, for one month) reduced the expression of
ICAM-1, VCAM-1, IL-8 and mRNA of inflammatory and adhesion molecules in 44 healthy subjects.
The inflammatory markers are related with atherosclerosis and oxidative stress. Thus, resveratrol
intake could represents a preventive measure for the onset of atherosclerosis [215].
Zunino et al. investigated the effects of dietary grapes in a randomized, double-blind crossover
study in 24 obese human subjects. The obesity is associated with a major risk of cardiovascular
diseases. The authors reported that dietary grape powder supplementation (46 g, two times per
day for 3 weeks) reduced the plasma concentration of LDL and increased the production of IL-1β
and IL-6 in supernatants from lipopolysaccharide-activated peripheral blood mononuclear cells
(PBMCs) [216]. Zern et al. observed that the grape powder supplementation (36 g, per day for
4 weeks) showed an improvement in plasma lipids, inflammatory cytokines, and oxidative stress in
24 pre- and 20 post-menopausal women. This trial suggested that grape powder can influence the
expression of key risk factors for coronary heart disease in pre- and post-menopausal women [217].
Vaisman and Niv showed that red grape cell powder consumption (200 or 400 mg, per day for
12 weeks) improved the endothelial function, diastolic blood pressure and reduced oxidative stress
without adverse effects in 50 subjects with pre-hypertension and mild hypertension [218]. However,
several randomized placebo-controlled trials did not show differences between placebo and treated
groups [212]. For example, in a double-blind, randomized crossover trial, Mellen and colleagues
reported that the muscadine grape seed supplementation (1300 mg, per day for 4 weeks) did not
improve endothelial function, blood pressure or did not change the plasma markers of cardiovascular
risk in 50 subjects with increased cardiovascular risk [219].
Several studies reported the improvement of blood pressure after cocoa intake, in particular
dark chocolate, in hypertensive subjects and with endothelial dysfunction. It has been reported
that flavanol-enriched cocoa drink increased the levels of NO and NOS activity by improving the
endothelial dysfunction. But some trials did not show this effects both in short treatments and in
supplementation of one year with 27 g flavonoid-enriched chocolate [212].
Overall, the conclusions that may be drawn from clinical trials are much different from in vitro
and in vivo studies. Indeed, results from human trials employing polyphenols showed a controversial
response [212].
7. Limitations of the Polyphenols Studies
Overall, although in vitro studies were necessary to determine the polyphenols effective dose and
their mechanism of action, they have some limitations. One of the major drawback of in vitro studies
is the use of polyphenols in the aglycones form or in coniugation with sugar moieties and not the use
of the active metabolites. In addition, the effective doses were much higher than the concentrations
that can be reached in humans. Accordingly, the in vitro results must be carefully decoded.
The results obtained from in vivo studies also have some limitations. Indeed, the majority of the
information regarding the metabolism and distribution of polyphenols in target tissues is the results
of animal studies. However, the metabolism, the genome, the physiology and colonic microflora
of animals are much different from those of humans. Accordingly, these results are needed to be
carefully translated in humans. In addition, a variety of employed animal models does not mimic the
progression of the human disease.
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The controversial results obtained from human trials might reflect these drawbacks and further
be amplified by the human inter-individual variability in the colonic microflora composition that
might affect the absorption and the production of the polyphenol active metabolites. In addition,
the number of participants in many human studies might be too low and the observation time too
short for obtaining an unbeatable result.
Finally, a better knowledge of polyphenols interaction is required for understanding the
polyphenols beneficial effects observed in epidemiological studies.
8. Conclusions
Polyphenols possess many biological activities, including anti-oxidant, anti-inflammatory,
anti-microbial, anti-viral and anti-cancer properties. Several epidemiological studies have shown a
relation between a diet rich in polyphenols and the prevention of various human diseases.
Cardiovascular diseases are the mainly cause of mortality and morbidity in the world. Overall,
several in vitro and in vivo studies demonstrated the ability of polyphenols to counteract oxidative
stress-induced cardiomyocytes damage and death. Polyphenols exert long-lasting effects compared
to other direct anti-oxidant agents, because they induce a transcription-mediated signaling, thus
activating endogenous anti-oxidant enzymatic defense systems.
In light of the results from in vitro, in vivo and in some clinical trials, and of the activity of
polyphenols in the regulation of oxidative stress and inflammation, polyphenols could be useful
for the design of novel agents for the treatment of cardiovascular diseases [213]. However, it is
necessary a better understanding of the reason why not all individuals show cardiovascular benefits
after administration with dietary polyphenols. This knowledge is essential for the universal and
definite acceptance of the clinical usefulness of polyphenols in cardiovascular disease.
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